Atonomics and OMRON Healthcare Enter Agreement for Equity Investment

COPENHAGEN, Denmark, December 9, 2013 /PRNewswire/ --

Investment will Aid Atonomics in Development of an Advanced Platform for Testing of Lifestyle Diseases

     (Logo: http://photos.prnewswire.com/prnh/20121126/578019 )

Atonomics announces today that it has entered into an agreement with Omron Healthcare, which will enable Atonomics to advance the development of the Atolyzer®Consumer device for advanced diagnostic testing of lifestyle diseases in a consumer pharmacy setting. As part of the transaction Omron Healthcare is taking a minority equity stake in Atonomics.

The Atolyzer®Consumer device is the initial product line under the Atolyzer®Platform, a fully integrated immuno-, metabolic-, and molecular diagnostic platform, designed to deliver central laboratory performance in a near-patient environment. The platform consists of three devices currently under development: Atolyzer®Consumer, Atolyzer®PoC and Atolyzer®Gene.

Atonomics is targeting to create a paradigm shift in how lifestyle diseases are managed today. "We want to change the way people are going to controls at the GP office for a yearly check-up of their type-2 diabetes or heart problem to be able in the future additionally to monitor and manage their disease status actively towards less disease complications and simply a better quality of life," says Thomas Warthoe, Atonomics' CEO.

"The Atolyzer®Consumer device combines small size, ease of use, portability and low cost in a system that is based on well-established chemistries, reagents, and technologies. We look forward to assisting Atonomics in moving this technology towards commercialization," says Kiichiro Miyata, President and CEO of Omron Healthcare.

This collaboration re-emphasizes the development pathway that Atonomics has embarked upon, and duly stresses the need to offer cost effective convenience based point-of care diagnostics in the molecular space. We welcome the addition to our existing impressive syndicate, which includes Beckman Coulter, of Omron, a world-class consumer-oriented company, which has clearly recognized our strategic vision. We look forward to working together in bringing this offering to the consumer", says Ashok Dhanrajgir, Board Director at Atonomics and Senior Partner at Inventages.

About Atonomics

Atonomics is an emerging technology company based in Copenhagen, Denmark that designs and manufactures the innovative Atolyzer®Platform for near-patient testing and monitoring in pharmacies, clinics, physician offices and hospitals. Atonomics is pursuing a strategy to partner with leading players in the industry to bring a new dimension of quality to the decentral Dx testing segments. The Atolyzer® is designed for simplicity and ease of use while preserving performance and safety. The stand-alone device is operated with a single touch by any person and can be positioned in any location where larger systems cannot operate, representing true near-patient testing.

About Omron Healthcare

Committed to improving people's lives, Omron Healthcare provides clinically proven, innovative medical equipment for health monitoring and therapy. Our product portfolio includes blood pressure monitors, respiratory devices, electronic fever thermometers, blood glucose monitors and activity monitors as well as body composition monitors and professional medical devices. For many decades Omron's devices have helped people to prevent, treat and manage lifestyle diseases both at home and in clinical practice in more than 100 countries around the world. Omron Healthcare Group is headquartered in Kyoto, Japan. Omron Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 60 countries through a powerful distribution network.

Contacts:

Atonomics
Thomas Warthoe, CEO
Phone: +45-70271330
E-mail: [email protected]
Web: http://www.atonomics.com

SOURCE Atonomics A/S

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED